Capital Network analyst Riccardo Lowi discusses Avacta Group Plc (LON:AVCT) following the release of its preliminary results.
Lowi says over the last year or so, management's delivered significant progress in bringing their Affimer platform into the commercial stage, across both therapeutics and diagnostic applications.